HRMY vs. KURA, EWTX, GPCR, NAMS, SNDX, SDGR, TARO, ARDX, RCUS, and LGND
Should you be buying Harmony Biosciences stock or one of its competitors? The main competitors of Harmony Biosciences include Kura Oncology (KURA), Edgewise Therapeutics (EWTX), Structure Therapeutics (GPCR), NewAmsterdam Pharma (NAMS), Syndax Pharmaceuticals (SNDX), Schrödinger (SDGR), Taro Pharmaceutical Industries (TARO), Ardelyx (ARDX), Arcus Biosciences (RCUS), and Ligand Pharmaceuticals (LGND). These companies are all part of the "pharmaceutical preparations" industry.
Kura Oncology (NASDAQ:KURA) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.
Kura Oncology received 362 more outperform votes than Harmony Biosciences when rated by MarketBeat users. Likewise, 69.01% of users gave Kura Oncology an outperform vote while only 60.29% of users gave Harmony Biosciences an outperform vote.
Kura Oncology has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500.
Harmony Biosciences has a net margin of 22.30% compared to Harmony Biosciences' net margin of 0.00%. Kura Oncology's return on equity of 28.26% beat Harmony Biosciences' return on equity.
Harmony Biosciences has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.
Kura Oncology currently has a consensus target price of $27.94, indicating a potential upside of 30.00%. Harmony Biosciences has a consensus target price of $40.63, indicating a potential upside of 37.57%. Given Kura Oncology's higher possible upside, analysts clearly believe Harmony Biosciences is more favorable than Kura Oncology.
86.2% of Harmony Biosciences shares are held by institutional investors. 5.5% of Kura Oncology shares are held by company insiders. Comparatively, 30.8% of Harmony Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Kura Oncology had 1 more articles in the media than Harmony Biosciences. MarketBeat recorded 4 mentions for Kura Oncology and 3 mentions for Harmony Biosciences. Kura Oncology's average media sentiment score of 1.90 beat Harmony Biosciences' score of 1.39 indicating that Harmony Biosciences is being referred to more favorably in the news media.
Summary
Harmony Biosciences beats Kura Oncology on 11 of the 16 factors compared between the two stocks.
Get Harmony Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Harmony Biosciences Competitors List
Related Companies and Tools
